FOR PATIENTS WITH IgAN
Click on image to enlarge.
FOR ADULTS WITH PRIMARY IgAN AT RISK OF RAPID DISEASE PROGRESSION (GENERALLY A UPCR ≥1.5 g/g)1
Click on image to enlarge.
WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA
FABHALTA, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life threatening or fatal if not recognized and treated early.
Because of the risk of serious infections caused by encapsulated bacteria, FABHALTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FABHALTA REMS.
FABHALTA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether FABHALTA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
Definitions
C3, complement 3; C3b, complement 3b; C5, complement 5; IgAN, immunoglobulin A nephropathy; UPCR urine protein-to-creatinine ratio.
References
1. Fabhalta. Prescribing information. Novartis Pharmaceuticals Corp.
2. Lim RS, Yeo SC, Barratt J, Rizk DV. An update on current therapeutic options in IgA nephropathy. J Clin Med. 2024;13(4):947. doi:10.3390/jcm13040947
3. Medjeral-Thomas NR, Troldborg A, Constantinou N, et al. Progressive IgA nephropathy is associated with low circulating mannan-binding lectin–associated serine protease-3 (MASP-3) and increased glomerular factor H–related protein-5 (FHR5) deposition. Kidney Int Rep. 2018;3(2):426-438. doi:10.1016/j.ekir.2017.11.015
4. Lai KN, Tang SC, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001. doi:10.1038/nrdp.2016.1